Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

Shares of weight loss and diabetes medication maker Novo Nordisk (NYSE: NVO) have slumped precipitously over the past 52 ...

Pharmaceutical giant Novo Nordisk (NYSE: NVO) released its fourth-quarter and full-year earnings report on Feb. 5. Here are two important insights from that call that should excite investors about ...

Research links weight loss medications like Ozempic and Zepbound to certain serious eye conditions.

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

We recently compiled a list of the 14 Best Large Cap Dividend Growth Stocks To Buy Now. In this article, we are going to take ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

A new study suggests popular weight-loss drugs like Ozempic and Zepbound may be linked to rare eye conditions that could ...

A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and ...

Beyond treating diabetes and helping people lose weight, GLP-1s may also improve libido. But the reasons are as complex as ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...